Renal injury in angiotensin II+L-NAME-induced hypertensive rats is independent of elevated blood pressure

American Journal of Physiology - Renal Physiology

Volumn 300, Issue 4, 2011, Pages 1008-1016

  Polichnowski, Aaron J ^a   Lu, Limin ^a   Cowley, Allen W ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Angiotensin II; Hypertension; Inflammation; Nitric oxide; Oxidative stress

Indexed keywords

ANGIOTENSIN II; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA BALLOON; ARTICLE; BLOOD PRESSURE; CELL INFILTRATION; CLIP; CONTROLLED STUDY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY ARTERY; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY MEDULLA; KIDNEY TUBULE DAMAGE; MACROPHAGE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RAT;

EID: 79954469664     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00354.2010     Document Type: Article

References (49)

1. Adam A, Raij L. Nitric oxide-angiotensin II axis in renal and cardiovascular injury. J Nephrol 13: 211-220, 2000.
2. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 44: 595-601, 2004.
3. Bidani AK, Griffin KA, Williamson G, Wang X, Loutzenhiser R. Protective importance of the myogenic response in the renal circulation. Hypertension 54: 393-398, 2009.
4. Cao CC, Ding XQ, Ou ZL, Liu CF, Li P, Wang L, Zhu CF. In vivo transfection of NF-kappaB decoy oligodeoxynucleotides attenuate renal ischemia/reperfusion injury in rats. Kidney Int 65: 834-845, 2004.
5. Cowley AW. Renal medullary oxidative stress, pressure-natriuresis, and hypertension. Hypertension 52: 777-786, 2008.
6. Cowley AW. Role of the renal medulla in volume and arterial pressure regulation. Am J Physiol Regul Integr Comp Physiol 273: R1-R15, 1997.
7. Crowley SD, Frey CW, Gould SK, Griffiths R, Ruiz P, Burchette JL, Howell DN, Makhanova N, Yan M, Kim HS, Tharaux PL, Coffman TM. Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol 295: F515-F524, 2008.
8. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA, Shin WS, Liao JK. Nitric oxide decreases cytokine-induced endothelial activation Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 96: 60-68, 1995.
9. Deng X, Welch WJ, Wilcox CS. Role of nitric oxide in short-term and prolonged effects of angiotensin II on renal hemodynamics. Hypertension 27: 1173-1179, 1996.
10. Fogo AB. Hypertensive risk factors in kidney disease in African Americans. Kidney Int Suppl: S17-S21, 2003.
11. Franco M, Martinez F, Quiroz Y, Galicia O, Bautista R, Johnson RJ, Rodriguez-Iturbe B. Renal angiotensin II concentration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol 293: R251-R256, 2007.
12. Henke N, Schmidt-Ullrich R, Dechend R, Park JK, Qadri F, Wellner M, Obst M, Gross V, Dietz R, Luft FC, Scheidereit C, Muller DN. Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ Res 101: 268-276, 2007.
13. Hu L, Sealey JE, Chen R, Zhou Y, Merali C, Shi Y, Laragh JH, Catanzaro DF. Nitric oxide synthase inhibition accelerates the pressor response to low-dose angiotensin II, exacerbates target organ damage, and induces renin escape. Am J Hypertens 17: 395-403, 2004.
14. Ikenaga H, Fallet RW, Carmines PK. Basal nitric oxide production curtails arteriolar vasoconstrictor responses to ANG II in rat kidney. Am J Physiol Renal Fluid Electrolyte Physiol 271: F365-F373, 1996.
15. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, Schwartz SM. Renal injury from angiotensin II-mediated hypertension. Hypertension 19: 464-474, 1992.
16. Johnson RJ, Schreiner GF. Hypothesis: the role of acquired tubuloin-terstitial disease in the pathogenesis of salt-dependent hypertension. Kidney Int 52: 1169-1179, 1997.
17. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS. MYH9 is associated with nondi-abetic end-stage renal disease in African Americans. Nat Genet 40: 1185-1192, 2008.
18. Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE. Recommendations for blood pressure measurement in humans and experimental animals. Part 2: blood pressure measurement in experimental animals: a statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. Hypertension 45: 299-310, 2005.
19. Leon CA, Raij L. Interaction of haemodynamic and metabolic pathways in the genesis of diabetic nephropathy. J Hypertens 23: 1931-1937, 2005.
20. Liang HL, Hilton G, Mortensen J, Regner K, Johnson CP, Nilakantan V. MnTMPyP, a cell-permeant SOD mimetic, reduces oxidative stress and apoptosis following renal ischemia-reperfusion. Am J Physiol Renal Physiol 296: F266-F276, 2009.
21. Liao TD, Yang XP, Liu YH, Shesely EG, Cavasin MA, Kuziel WA, Pagano PJ, Carretero OA. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension 52: 256-263, 2008.
22. Mattson DL, James L, Berdan EA, Meister CJ. Immune suppression attenuates hypertension and renal disease in the Dahl salt-sensitive rat. Hypertension 48: 149-156, 2006.
23. Mattson DL, Lu S, Roman RJ, Cowley AW. Relationship between renal perfusion pressure and blood flow in different regions of the kidney. Am J Physiol Regul Integr Comp Physiol 264: R578-R583, 1993.
24. Mori T, Cowley AW. Role of pressure in angiotensin II-induced renal injury: chronic servo-control of renal perfusion pressure in rats. Hypertension 43: 752-759, 2004.
25. Mori T, Polichnowski A, Glocka P, Kaldunski M, Ohsaki Y, Liang M, Cowley AW. High perfusion pressure accelerates renal injury in salt-sensitive hypertension. J Am Soc Nephrol 19: 1472-1482, 2008.
26. Nakagawa T, Kang DH, Ohashi R, Suga S, Herrera-Acosta J, Rodri-guez-Iturbe B, Johnson RJ. Tubulointerstitial disease: role of ischemia and microvascular disease. Curr Opin Nephrol Hypertens 12: 233-241, 2003.
27. Nishiyama A, Fujisawa Y, Fukui T, Rahman M, Kondo N, Ogawa Y, Fanzhu L, Guoxing Z, Kimura S, Abe Y. Role of nitric oxide in regional blood flow in angiotensin II-induced hypertensive rats. Hypertens Res 24: 421-427, 2001.
28. Palm F, Cederberg J, Hansell P, Liss P, Carlsson PO. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabe-tologia 46: 1153-1160, 2003.
29. Polichnowski AJ, Cowley AW. Pressure-induced renal injury in angiotensin II versus norepinephrine-induced hypertensive rats. Hypertension 54: 1269-1277, 2009.
30. Polichnowski AJ, Jin C, Yang C, Cowley AW. Role of renal perfusion pressure versus angiotensin II on renal oxidative stress in angiotensin II-induced hypertensive rats. Hypertension 55: 1425-1430, 2009.
31. Quiroz Y, Bravo J, Herrera-Acosta J, Johnson RJ, Rodriguez-Iturbe B. Apoptosis and NFkappaB activation are simultaneously induced in renal tubulointerstitium in experimental hypertension. Kidney Int Suppl: S27-S32, 2003.
32. Quiroz Y, Pons H, Gordon KL, Rincon J, Chavez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, Johnson RJ, Rodriguez-Iturbe B. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol 281: F38-F47, 2001.
33. Raij L. Workshop: hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension 37: 767-773, 2001.
34. Rodriguez-Iturbe B, Pons H, Herrera-Acosta J, Johnson RJ. Role of immunocompetent cells in nonimmune renal diseases. Kidney Int 59: 1626-1640, 2001.
35. Rodriguez-Iturbe B, Pons H, Quiroz Y, Gordon K, Rincon J, Chavez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, Johnson RJ. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 59: 2222-2232, 2001.
36. Ruggenenti P, Perna A, Zoccali C, Gherardi G, Benini R, Testa A, Remuzzi G. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). J Am Soc Nephrol 11: 88-96, 2000.
37. Schnackenberg CG, Wilcox CS. Two-week administration of tempol attenuates both hypertension and renal excretion of 8-iso prostaglandin f2alpha. Hypertension 33: 424-428, 1999.
38. Schulman IH, Zhou MS, Raij L. Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension. J Hypertens Suppl 24: S45-S50, 2006.
39. Singaravelu K, Devalaraja-Narashimha K, Lastovica B, Padanilam BJ. PERP, a p53 proapoptotic target, mediates apoptotic cell death in renal ischemia. Am J Physiol Renal Physiol 296: F847-F858, 2009.
40. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 100: 264-269, 1997.
41. Szentivanyi M Jr, Maeda CY, Cowley AW. Local renal medullary l-NAME infusion enhances the effect of long-term angiotensin II treatment. Hypertension 33: 440-445, 1999.
42. Taylor NE, Glocka P, Liang M, Cowley AW. NADPH oxidase in the renal medulla causes oxidative stress and contributes to salt-sensitive hypertension in Dahl S rats. Hypertension 47: 692-698, 2006.
43. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects The MRFIT Research Group. JAMA 268: 3085-3091, 1992.
44. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 289: R913-R935, 2005.
45. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288: 2421-2431, 2002.
46. Yuan B, Liang M, Yang Z, Rute E, Taylor N, Olivier M, Cowley AW. Gene expression reveals vulnerability to oxidative stress and interstitial fibrosis of renal outer medulla to nonhypertensive elevations of ANG II. Am J Physiol Regul Integr Comp Physiol 284: R1219-R1230, 2003.
47. Zhang Z, Rhinehart K, Solis G, Pittner J, Lee-Kwon W, Welch WJ, Wilcox CS, Pallone TL. Chronic ANG II infusion increases NO generation by rat descending vasa recta. Am J Physiol Heart Circ Physiol 288: H29-H36, 2005.
48. Zhou MS, Schulman IH, Raij L. Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 24: 366-378, 2004.
49. Zou AP, Wu F, Cowley AW. Protective effect of angiotensin II-induced increase in nitric oxide in the renal medullary circulation. Hypertension 31: 271-276, 1998.